C-reactive protein impairs immune response of CD8 + T cells via FcI 3RIIb-p38MAPK-ROS axis in multiple myeloma
Journal for ImmunoTherapy of Cancer, ISSN: 2051-1426, Vol: 11, Issue: 10
2023
- 11Citations
- 15Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes11
- 11
- CrossRef1
- Captures15
- Readers15
- 15
- Mentions1
- News Mentions1
- 1
Most Recent News
Researchers from Shanghai Jiao Tong University School of Medicine Describe Findings in Multiple Myeloma (C-reactive protein impairs immune response of CD8+ T cells via FcgRIIb-p38MAPK-ROS axis in multiple myeloma)
2023 NOV 01 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- A new study on multiple myeloma is now available. According
Article Description
Background C-reactive protein (CRP) is a prototypical acute phase protein in humans with the function of regulating immune cells. Serum CRP levels are elevated in multiple myeloma (MM), associated with MM cell proliferation and bone destruction. However, its direct effects on T lymphocytes in MM have not been elucidated. Methods Public data sets were used to explore the correlation of CRP levels with immune cell infiltration and cytotoxicity score of CD8 + T cells in MM. In vitro, repeated freeze-Thaw myeloma cell lines were taken as tumor antigens to load dendritic cells (DCs) derived from HLA-A∗0201-positive healthy donors. MM-specific cytotoxic T cells (MM-CTL) were obtained from T lymphocytes of the corresponding donors pulsed with these DCs. B-cell maturation antigen (BCMA)-Targeted chimeric antigen receptor (CAR)-T cells were manipulated by transfecting with lentivirus encoding an anti-BCMA single-chain variable fragment. Then T cells from healthy controls, MM-CTLs and BCMA CAR-T cells were exposed to CRP and analyzed for cell proliferation, cytotoxicity, immunophenotypes. CRP binding capacity to T cells before and after Fc gamma receptors IIb (FcI 3RIIb) blockage, p38 mitogen-Activated protein kinase (MAPK) pathway and the downstream molecules were also detected. In vivo, both normal C57BL/6J mice and the Vk∗MYC myeloma mouse models were applied to confirm the impact of CRP on T cells. Results CRP levels were negatively correlated with cell-infiltration and cytotoxicity score of CD8 + T cells in MM. In vitro experiments showed that CRP inhibited T-cell proliferation in a dose-dependent manner, impaired the cytotoxic activity and upregulated expression of senescent markers in CD8 + T cells. In vivo results validated the suppressive role of CRP in CD8 + T cells. CRP could bind to CD8 + T cells, mainly to the naïve T subset, while the binding was dramatically decreased by FcI 3RIIb blockage. Furthermore, CRP resulted in increased phosphorylation of p38 MAPK, elevated levels of reactive oxygen species and oxidized glutathione in CD8 + T cells. Conclusions We found that CRP impaired immune response of CD8 + T cells via FcI 3RIIb-p38MAPK-ROS signaling pathway. The study casted new insights into the role of CRP in anti-myeloma immunity, providing implications for future immunotherapy in MM.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85174642010&origin=inward; http://dx.doi.org/10.1136/jitc-2023-007593; http://www.ncbi.nlm.nih.gov/pubmed/37844994; https://jitc.bmj.com/lookup/doi/10.1136/jitc-2023-007593; https://dx.doi.org/10.1136/jitc-2023-007593; https://jitc.bmj.com/content/11/10/e007593
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know